Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
We explored the association of a variety of factors including endoscopic activity of patients in clinical remission with their long-term clinical outcome. Mayo endoscopic score 1 (hazard ratio (HR): 2.86) and score 2 (HR: 3.60) was significant risk factor for clinical relapse against endoscopic score 0. Univariate analysis also identified significant association with relapse for moderate clinical activity of last flare, remission induction with cytapheresis (CAP), maintenance with imuunomodulator, shorter duration of remission and higher histological activity. Cox regression analysis revealed that endoscopic activity, histological activity, duration of remission and remission induction with CAP were found to be independent determinants of relapse. The Kaplan-Meier estimate of non-relapse rate by endoscopic activity groups demonstrated significant difference. While there was significance between score 0 and 1, there were no significance between score 1 and 2.
|